MedTrace Logo

To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg

NCT00946725 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2017-03-28

No results posted yet for this study

Summary

To demonstrate the relative bioavailability of atenolol tablets, 100 mg.

Conditions

Interventions

DRUG

Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)

DRUG

Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)

Sponsors & Collaborators

Principal Investigators

  • Ronald Goldwater, M.D. · PharmaKinetics Laboratories Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-11-30
Primary Completion
2000-11-30
Completion
2000-11-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00946725 on ClinicalTrials.gov